PD-1抑制剂联合仑伐替尼治疗晚期肝癌的疗效分析
付慧英 柯传庆 章柏平 彭恩兰摘 要 目的:探討分析PD-1抑制剂联合仑伐替尼治疗晚期肝癌临床效果和不良反应。方法:将66例晚期肝癌患者随机分为对照组(n=33,给予仑伐替尼治疗)和观察组(n=33,给予PD-1抑制剂联合仑伐替尼治疗),对比两组临床治疗效果和不良发生情况。结果:观察组肝区疼痛缓解有效率高于对照组(81.8% vs 54.5%),不良反应发生率低于对照组(12.1% vs 45.5%),靶病灶治疗总有效率高于对照组(75% vs 45%,均P<0.05)。结论:PD-1抑制剂联合仑伐替尼治疗晚期肝癌临床效果显著,且可降低不良反应发生率。
关键词 晚期肝癌 PD-1抑制剂 仑伐替尼 临床效果 不良反应
中图分类号:R979.19; R735.7 文献标志码:B 文章编号:1006-1533(2022)03-0029-02
Analysis of efficacy of PD-1 inhibitor combined with renvatinib in the treatment of advanced liver cancer
FU Huiying, KE Chuanqing, ZHANG Baiping, PENG Enlan(Department of Oncology, 908 Hospital, Joint Service Support Force of the Chinese People’s Liberation Army, Nanchang 330000, China)
ABSTRACT Objective: To investigate the clinical effect and adverse reactions of PD-1 inhibitor combined with renvatinib in the treatment of advanced liver cancer. Methods: Sixty-six patients with advanced liver cancer were randomly divided into a control group (n=33 ......
您现在查看是摘要页,全文长 7790 字符。